{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:46:25Z","timestamp":1792586785698,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T00:00:00Z","timestamp":1789430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National Pharmaceutical Council","id":[{"id":"https:\/\/ror.org\/027608a92","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Appl Health Econ Health Policy"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s40258-026-01064-0","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T17:11:42Z","timestamp":1789492302000},"page":"1029-1037","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Estimating the Share of Social Surplus Generated by Pharmaceutical Innovation Accruing to Manufacturers: A Systematic Literature Review"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2424-7852","authenticated-orcid":false,"given":"Robert J.","family":"Nordyke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7248-4890","authenticated-orcid":false,"given":"Tyler D.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreeranjani","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,15]]},"reference":[{"key":"1064_CR1","doi-asserted-by":"publisher","unstructured":"Finston SK, Davey NS, Chakrabarty AM, Dav\u00e9 RS. The Biopharmaceutical Social Contract and U.S. Patent Social Contract: Historical Antecedents and Recent Developments. In: Singh H, Keswani C, Singh S (eds) Intellectual property issues in microbiology. 2019. Springer, Singapore. https:\/\/doi.org\/10.1007\/978-981-13-7466-1_15.","DOI":"10.1007\/978-981-13-7466-1_15"},{"key":"1064_CR2","unstructured":"Lemmens T, Ghimire KM, Perehudoff K, et al. The Social Contract and Human Rights Bases for Promoting Access to Effective, Novel, High-Priced Medicines [Internet]. Copenhagen \u00d8, Denmark: World Health Organization; 2022. 1 Introduction: social contract, social goods and human rights approaches. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK587887\/. Accessed 6 June 2025."},{"issue":"1","key":"1064_CR3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1377\/hlthaff.26.1.97","volume":"26","author":"DM Cutler","year":"2007","unstructured":"Cutler DM, Long G, Berndt ER, Royer J, Fournier AA, Sasser A, et al. The value of antihypertensive drugs: a perspective on medical innovation. Health Aff (Millwood). 2007;26(1):97\u2013110. https:\/\/doi.org\/10.1377\/hlthaff.26.1.97.","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"1064_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.hlpt.2013.09.005","volume":"3","author":"FR Lichtenberg","year":"2014","unstructured":"Lichtenberg FR. Pharmaceutical innovation and longevity growth in 30 developing and high-income countries, 2000\u20132009. Health Policy Technol. 2014;3(1):36\u201358. https:\/\/doi.org\/10.1016\/j.hlpt.2013.09.005.","journal-title":"Health Policy Technol"},{"issue":"9","key":"1064_CR5","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1377\/hlthaff.2020.00284","volume":"39","author":"JD Buxbaum","year":"2020","unstructured":"Buxbaum JD, Chernew ME, Fendrick AM, Cutler DM. Contributions of Public Health, Pharmaceuticals, And Other Medical Care to US Life Expectancy Changes, 1990\u20132015. Health Aff (Millwood). 2020;39(9):1546\u201356. https:\/\/doi.org\/10.1377\/hlthaff.2020.00284.","journal-title":"Health Aff (Millwood)."},{"issue":"10441","key":"1064_CR6","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/S0140-6736(24)00850-X","volume":"403","author":"AJ Shattock","year":"2024","unstructured":"Shattock AJ, Johnson HC, Sim SY, Carter A, Lambach P, Hutubessy RCW, et al. Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization. Lancet. 2024;403(10441):2307\u201316. https:\/\/doi.org\/10.1016\/S0140-6736(24)00850-X.","journal-title":"Lancet"},{"issue":"23","key":"1064_CR7","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1056\/NEJMsa053935","volume":"356","author":"ES Ford","year":"2007","unstructured":"Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007;356(23):2388\u201398. https:\/\/doi.org\/10.1056\/NEJMsa053935.","journal-title":"N Engl J Med"},{"issue":"7","key":"1064_CR8","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.socscimed.2009.11.033","volume":"70","author":"J Schnittker","year":"2010","unstructured":"Schnittker J, Karandinos G. Methuselah\u2019s medicine: pharmaceutical innovation and mortality in the United States, 1960-2000. Soc Sci Med. 2010;70(7):961\u20138. https:\/\/doi.org\/10.1016\/j.socscimed.2009.11.033.","journal-title":"Soc Sci Med"},{"issue":"9","key":"1064_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1001\/jama.2022.14733","volume":"323","author":"DM Cutler","year":"2020","unstructured":"Cutler DM. Are Pharmaceutical Companies Earning Too Much? JAMA. 2020;323(9):829\u201330. https:\/\/doi.org\/10.1001\/jama.2022.14733.","journal-title":"JAMA"},{"issue":"2","key":"1064_CR10","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40273-023-01325-z","volume":"42","author":"M Paulden","year":"2024","unstructured":"Paulden M. A framework for the fair pricing of medicines. Pharmacoeconomics. 2024;42(2):145\u201364. https:\/\/doi.org\/10.1007\/s40273-023-01325-z.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"1064_CR11","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10198-013-0484-1","volume":"15","author":"R Refoios Camejo","year":"2014","unstructured":"Refoios Camejo R, McGrath C, Miraldo M, Rutten F. Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD. Eur J Health Econ. 2014;15(4):439\u201345. https:\/\/doi.org\/10.1007\/s10198-013-0484-1.","journal-title":"Eur J Health Econ"},{"issue":"2","key":"1064_CR12","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1515\/fhep-2024-0049","volume":"27","author":"TJ Philipson","year":"2025","unstructured":"Philipson TJ, Fendrick AM, Kataria A, Di Cera G, Zhao Q, Guo S, et al. COVID-19 biopharmaceutical innovation and industry appropriation. Forum Health Econ Policy. 2025;27(2):117\u201346. https:\/\/doi.org\/10.1515\/fhep-2024-0049.","journal-title":"Forum Health Econ Policy"},{"issue":"11","key":"1064_CR13","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1002\/hec.4393","volume":"30","author":"B Woods","year":"2021","unstructured":"Woods B, Fox A, Sculpher M, Claxton K. Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems. Health Econ. 2021;30(11):2649\u201366. https:\/\/doi.org\/10.1002\/hec.4393.","journal-title":"Health Econ"},{"issue":"10","key":"1064_CR14","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.ijsu.2010.02.007","volume":"62","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006\u201312. https:\/\/doi.org\/10.1016\/j.ijsu.2010.02.007.","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"1064_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/20016689.2020.1717030","volume":"8","author":"JA McDougall","year":"2020","unstructured":"McDougall JA, Furnback WE, Wang BCM, Mahlich J. Understanding the global measurement of willingness to pay in health. J Mark Access Health Policy. 2020;8(1):1717030. https:\/\/doi.org\/10.1080\/20016689.2020.1717030.","journal-title":"J Mark Access Health Policy"},{"issue":"4","key":"1064_CR16","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s10198-013-0484-1","volume":"15","author":"R Refoios Camejo","year":"2014","unstructured":"Refoios Camejo R, McGrath C, Miraldo M, Rutten F. Distribution of health- related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD. Eur J Health Econ. 2014;15(4):439\u201345. https:\/\/doi.org\/10.1007\/s10198-013-0484-1.","journal-title":"Eur J Health Econ"},{"key":"1064_CR17","doi-asserted-by":"crossref","unstructured":"Kakani P, Chernew M, Chandra A. Rebates in the pharmaceutical industry: Evidence from medicines sold in retail pharmacies in the us. National Bureau of Economic Research; 2020 Mar 16. Available at: https:\/\/www.nber.org\/papers\/w26846. Accessed 6 June 2025.","DOI":"10.3386\/w26846"},{"issue":"6","key":"1064_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.0626","volume":"2","author":"WB Feldman","year":"2021","unstructured":"Feldman WB, Rome BN, Raimond VC, Gagne JJ, Kesselheim AS. Estimating rebates and other discounts received by Medicare Part D. JAMA Health Forum. 2021;2(6):e210626. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.0626.","journal-title":"JAMA Health Forum"},{"key":"1064_CR19","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ahj.2018.08.006","volume":"206","author":"KA Schulman","year":"2018","unstructured":"Schulman KA, Dabora M. The relationship between pharmacy benefit managers (PBMs) and the cost of therapies in the US pharmaceutical market: a policy primer for clinicians. Am Heart J. 2018;206:113\u201322. https:\/\/doi.org\/10.1016\/j.ahj.2018.08.006.","journal-title":"Am Heart J"},{"issue":"11","key":"1064_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamahealthforum.2021.3409","volume":"2","author":"K Van Nuys","year":"2021","unstructured":"Van Nuys K, Ribero R, Ryan M, Sood N. Estimation of the share of net expenditures on insulin captured by US manufacturers, wholesalers, pharmacy benefit managers, pharmacies, and health plans from 2014 to 2018. JAMA Health Forum. 2021;2(11):e213409. https:\/\/doi.org\/10.1001\/jamahealthforum.2021.3409.","journal-title":"JAMA Health Forum"},{"issue":"3","key":"1064_CR21","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.jval.2022.11.022","volume":"26","author":"M Berdud","year":"2023","unstructured":"Berdud M, Wallin-Bernhardsson N, Zamora B, Lindgren P, Towse A. The allocation of the economic value of second-generation antipsychotics over the product life cycle: the case of risperidone in Sweden and the United Kingdom. Value Health. 2023;26(3):328\u201335.","journal-title":"Value Health"},{"issue":"6","key":"1064_CR22","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10198-021-01409-7","volume":"23","author":"P Lindgren","year":"2022","unstructured":"Lindgren P, L\u00f6fvendahl S, Br\u00e5dvik G, Weiland O, J\u00f6nsson B. Value appropriation in hepatitis C. Eur J Health Econ. 2022;23(6):1059\u201370.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"1064_CR23","first-page":"41","volume":"23","author":"TJ Philipson","year":"2017","unstructured":"Philipson TJ, Thornton Snider J, Chit A, Green S, Hosbach P, Tinkham Schwartz T, et al. The social value of childhood vaccination in the United States. Am J Manag Care. 2017;23(1):41\u20137.","journal-title":"Am J Manag Care"},{"issue":"12","key":"1064_CR24","first-page":"e380","volume":"24","author":"JA Romley","year":"2018","unstructured":"Romley JA, Delgado A, Shim J, Batt K. The value of novel immuno-oncology treatments. Am J Manag Care. 2018;24(12):e380\u20135.","journal-title":"Am J Manag Care"},{"issue":"8","key":"1064_CR25","first-page":"379","volume":"25","author":"J Thornton Snider","year":"2019","unstructured":"Thornton Snider J, Brauer M, Kee R, Batt K, Karaca-Mandic P, Zhang J, et al. The potential impact of CAR T-cell treatment delays on society. Am J Manag Care. 2019;25(8):379\u201386.","journal-title":"Am J Manag Care"},{"issue":"4","key":"1064_CR26","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.jval.2022.01.010","volume":"25","author":"PJ Neumann","year":"2022","unstructured":"Neumann PJ, Garrison LP, Willke RJ. The history and future of the \u201cISPOR value flower\u201d: addressing limitations of conventional cost-effectiveness analysis. Value Health. 2022;25(4):558\u201365.","journal-title":"Value Health"},{"issue":"5","key":"1064_CR27","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/j.jhealeco.2008.05.010","volume":"27","author":"AB Jena","year":"2008","unstructured":"Jena AB, Philipson TJ. Cost-effectiveness analysis and innovation. J Health Econ. 2008;27(5):1224\u201336. https:\/\/doi.org\/10.1016\/j.jhealeco.2008.05.010.","journal-title":"J Health Econ"},{"issue":"4","key":"1064_CR28","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1002\/hec.4795","volume":"33","author":"B Woods","year":"2024","unstructured":"Woods B, Lomas J, Sculpher M, Weatherly H, Claxton K. Achieving dynamic efficiency in pharmaceutical innovation: identifying the optimal share of value and payments required. Health Econ. 2024;33(4):804\u201319. https:\/\/doi.org\/10.1002\/hec.4795.","journal-title":"Health Econ"},{"key":"1064_CR29","doi-asserted-by":"crossref","unstructured":"Basu A. Dynamic Efficiency and Pricing of Innovations with Insurance: The Case for Gene Therapies. National Bureau of Economic Research. Working Paper 32480; 2024 May 20. Available at: https:\/\/www.nber.org\/papers\/w32480. Accessed 6 June 2025.","DOI":"10.3386\/w32480"}],"container-title":["Applied Health Economics and Health Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01064-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-026-01064-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40258-026-01064-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T12:23:17Z","timestamp":1792585397000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40258-026-01064-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,15]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1064"],"URL":"https:\/\/doi.org\/10.1007\/s40258-026-01064-0","relation":{},"ISSN":["1175-5652","1179-1896"],"issn-type":[{"value":"1175-5652","type":"print"},{"value":"1179-1896","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,15]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"RJN, JR, and SM received contract funding from the National Pharmaceutical Council to conduct the analysis. TDW and JDC are employees of the National Pharmaceutical Council.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was based on existing literature, did not involve human subjects, and was exempt from ethics review.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All relevant data supporting the findings of this study are included in the results and supplementary materials.","order":3,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RJN contributed to study design; data abstraction and review; performed data analysis; contributed to results interpretation; drafted the first version of the manuscript. TDW contributed to study design; contributed to results interpretation; contributed to manuscript writing. JR contributed to study design; performed literature search and review; contributed to manuscript writing. SM contributed to literature search and review; contributed to manuscript writing. JDC contributed to study design; contributed to results interpretation; contributed to manuscript writing.","order":4,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":6,"name":"Ethics","label":"Consent for Publication (From Patients\/Participants)","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}